Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
3
Bullish
5
Bearish
7
Neutral
3
Bullish
36
Bearish
1
Neutral
0
Bullish
31
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1247.40 | 12,669 Cr | 42.44 | 7.39 | 0.28 | 17.05 | 17.00 | 10.09 | ||
223.85 | 9,669 Cr | 32.58 | 4.81 | 0.00 | 12.77 | 17.33 | 10.55 | ||
983.20 | 9,474 Cr | 52.15 | 5.05 | 0.00 | 9.85 | 11.09 | 7.65 | ||
605.40 | 9,039 Cr | 271.76 | 6.79 | 0.00 | 2.90 | 7.81 | 0.85 | ||
263.35 | 8,633 Cr | 46.26 | 5.30 | 0.08 | 11.43 | 12.76 | 7.29 | ||
732.50 | 7,926 Cr | 180.86 | 8.86 | 0.00 | 11.10 | 10.73 | 0.00 | ||
5881.05 | 6,434 Cr | 25.46 | 4.88 | 0.26 | 18.53 | 20.76 | 12.41 | ||
| Median: 7 Co. | — | 732.50 | 9,039 Cr | 46.26 | 5.30 | 0.00 | 11.43 | 12.76 | 7.65 |
Jupiter Life Line Hospitals operates multi-speciality tertiary and quaternary-care hospitals under the Jupiter brand across Thane, Pune, Indore and Dombivli, with 1,248 operational beds and more than 30 clinical specialties. Its network includes organ transplantation, oncology, cardiac care, neurology, robotic procedures and other advanced medical services across Western and Central India.
Q2 FY27 revenue reached INR456.5 crore, EBITDA was INR106.9 crore and PAT was INR56.4 crore, implying a strong quarterly EBITDA margin of approximately 23.4%. H1 FY27 revenue was INR867.5 crore, while EBITDA of INR186.2 crore reflected the continuing drag from Dombivli’s ramp-up and investment phase.
Dombivli’s EBITDA impact improved sharply from a INR9.5 crore loss in Q1 to approximately breakeven in Q2, although occupancy remained only in the mid-30s. Management attributed the improvement to organic ramp-up and seasonally higher infectious-disease admissions, cautioning that Q3 could moderate because occupancy is traditionally lower.
The company is strengthening long-term asset ownership by purchasing the 11,452-square-metre land beneath Pune South for INR150 crore, with INR50 crore already deposited. Management views ownership as providing greater control, certainty and long-term financial value, while the wider expansion pipeline is expected to be funded through internal accruals and debt.
Mature hospitals remain capacity-constrained growth assets: Thane operates near 75% occupancy and Pune near 70%, while Thane may receive additional beds subject to regulatory approval. New hospitals offer longer-term operating leverage through increasing occupancy, insurance empanelment, specialist hiring and migration toward higher-value tertiary and quaternary case mix.
Healthcare Services
Hospital
9,178 Cr
Low Risk
48.4
60.3
0.1
5.6
337.90
230.41
Sales CAGR
Profit CAGR
ROE
ROCE
Jupiter Life Line Hospitals Ltd (JLHL) is currently trading at 282.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jupiter Life Line Hospitals operates multi-speciality tertiary and quaternary-care hospitals under the Jupiter brand across Thane, Pune, Indore and Dombivli, with 1,248 operational beds and more than 30 clinical specialties. Its network includes organ transplantation, oncology, cardiac care, neurology, robotic procedures and other advanced medical services across Western and Central India. Q2 FY27 revenue reached INR456.5 crore, EBITDA was INR106.9 crore and PAT was INR56.4 crore, implying a strong quarterly EBITDA margin of approximately 23.4%. H1 FY27 revenue was INR867.5 crore, while EBITDA of INR186.2 crore reflected the continuing drag from Dombivli’s ramp-up and investment phase. Dombivli’s EBITDA impact improved sharply from a INR9.5 crore loss in Q1 to approximately breakeven in Q2, although occupancy remained only in the mid-30s. Management attributed the improvement to organic ramp-up and seasonally higher infectious-disease admissions, cautioning that Q3 could moderate because occupancy is traditionally lower. The company is strengthening long-term asset ownership by purchasing the 11,452-square-metre land beneath Pune South for INR150 crore, with INR50 crore already deposited. Management views ownership as providing greater control, certainty and long-term financial value, while the wider expansion pipeline is expected to be funded through internal accruals and debt. Mature hospitals remain capacity-constrained growth assets: Thane operates near 75% occupancy and Pune near 70%, while Thane may receive additional beds subject to regulatory approval. New hospitals offer longer-term operating leverage through increasing occupancy, insurance empanelment, specialist hiring and migration toward higher-value tertiary and quaternary case mix.
Over the past 52 weeks, Jupiter Life Line Hospitals Ltd has traded between a low of ₹230.41 and a high of ₹337.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jupiter Life Line Hospitals Ltd has a market capitalization of approximately 9,177.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jupiter Life Line Hospitals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,177.60 Cr, Jupiter Life Line Hospitals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jupiter Life Line Hospitals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jupiter Life Line Hospitals Ltd is 48.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Jupiter Life Line Hospitals reported consolidated total income of INR 456.5 crore for Q2 FY27.
The company reported Q1 FY27 consolidated revenue of Rs 411.0 crore (Rs 4,110 million), up 16% year-on-year.
The board recommended a 10% dividend, stated as INR 1 per equity share of face value INR 10, subject to shareholder approval at the AGM.
Jupiter Life Line Hospitals secured a 10,026.44 square meter plot in Mumbai's Bandra Kurla Complex on an 80-year lease from MMRDA for ₹354 crore to build a 400-bed hospital.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
